Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "NCEs"

2668 News Found

Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
Clinical Trials | October 09, 2022

Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial

Study achieves primary endpoint of radiographic progression-free survival


Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences
News | October 03, 2022

Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences

The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.


Lupin Life announces association with Vikram Vedha as official energy partner
News | October 02, 2022

Lupin Life announces association with Vikram Vedha as official energy partner

Enriched with eight ayurvedic active ingredients like Ashwagandha, Shilajit, Shatavari, and Pippali, Be One works holistically to provide energy, build immunity and enable a healthy body and mind


USFDA inspects Zydus Lifesciences Ahmedabad SEZ facility
Drug Approval | September 30, 2022

USFDA inspects Zydus Lifesciences Ahmedabad SEZ facility

The company will address the observations within a stipulated timeline working with the regulators


Puneet Sud appointed additional director of Nectar Lifesciences
People | September 26, 2022

Puneet Sud appointed additional director of Nectar Lifesciences

Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin


Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal
News | September 10, 2022

Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal

MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions


InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA
News | September 06, 2022

InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA

Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.


Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma
Clinical Trials | September 05, 2022

Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma

Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma